Literature DB >> 18666374

Pharmacokinetics and metabolic drug interactions.

Sorin E Leucuta1, Laurian Vlase.   

Abstract

Pharmacokinetics and drug metabolism play an important role as determinants of in vivo drug action. The CYP450 enzyme family plays a determinant role in the biotransformation of a vast number of structurally diverse drugs. Many drug interactions are a result of the inhibition or induction of CYP enzymes. The non-compartmental pharmacokinetic analysis is the most used method for analyzing data from a drug interaction study. Compartmental analysis can be also useful and sometimes more informative than non-compartmental analysis. Many efforts to reduce polypharmacy are important, and pharmacokinetic tools used to study the mechanism of drug-drug interactions may help in a better management of pharmacotherapy including the avoidance of clinically relevant drug interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18666374     DOI: 10.2174/157488406775268183

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  11 in total

1.  Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.

Authors:  Peter K Sand; Eric S Rovner; Jonathan H Watanabe; Michael G Oefelein
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Teddy Kosoglou; Yali Zhu; Fengjuan Xuan; Laura Black; Amy O Johnson-Levonas; Monika Martinho; Paul Statkevich; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

3.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 4.  [Personalised pharmacotherapy in intensive care unit patients].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-02       Impact factor: 0.840

5.  Characterizing metabolic inhibition using electrochemical enzyme/DNA biosensors.

Authors:  Dominic O Hull; Besnik Bajrami; Ingela Jansson; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2009-01-15       Impact factor: 6.986

6.  Incidence of Potential Drug-Drug Interaction and Related Factors in Hospitalized Neurological Patients in two Iranian Teaching Hospitals.

Authors:  Soha Namazi; Shiva Pourhatami; Afshin Borhani-Haghighi; Sareh Roosta
Journal:  Iran J Med Sci       Date:  2014-11

7.  Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5'-diphospho-glucuronosyltransferase isoforms.

Authors:  Munirah Haron; Sabariah Ismail
Journal:  Pharmacognosy Res       Date:  2014 Oct-Dec

8.  Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin.

Authors:  Wiriyaporn Sumsakul; Tullayakorn Plengsuriyakarn; Kesara Na-Bangchang
Journal:  BMC Pharmacol Toxicol       Date:  2016-11-14       Impact factor: 2.483

9.  Drug-drug interactions and pharmacists' interventions among psychiatric patients in outpatient clinics of a teaching hospital in Saudi Arabia.

Authors:  Yazed AlRuthia; Hadeel Alkofide; Fahad Dakheel Alosaimi; Ibrahim Sales; Albandari Alnasser; Aliah Aldahash; Lama Almutairi; Mohammed M AlHusayni; Miteb A Alanazi
Journal:  Saudi Pharm J       Date:  2019-05-13       Impact factor: 4.330

10.  A pilot study on the impact of known drug-drug interactions in cancer patients.

Authors:  Silvia Ussai; Riccardo Petelin; Antonio Giordano; Mario Malinconico; Donatella Cirillo; Francesca Pentimalli
Journal:  J Exp Clin Cancer Res       Date:  2015-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.